Inspire Medical Systems, Inc. (NYSE:INSP) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Consensus "Hold": Nineteen analysts give Inspire a consensus rating of "Hold" (1 sell, 13 hold, 5 buy) with an average 1-year target of $101.41, and several firms have recently trimmed price targets.
• Quarterly beat: Inspire reported $1.65 EPS vs. $0.69 expected and $269.1M revenue (up 12.2% YoY), while analysts expect $1.82 EPS for the current year.
• Valuation and ownership: The stock opened at $56.69 (52‑week range $48.30–$163.35), has a $1.63B market cap and 11.4x PE, and is heavily institutionally owned (94.91%).

Shares of Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) have been given an average recommendation of "Hold" by the nineteen analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $101.4118.

Several research firms have recently weighed in on INSP. Piper Sandler cut their price objective on Inspire Medical Systems from $165.00 to $85.00 and set an "overweight" rating on the stock in a report on Thursday, February 12th. Stifel Nicolaus cut their price objective on Inspire Medical Systems from $85.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 10th. Truist Financial cut their price objective on Inspire Medical Systems from $70.00 to $64.00 and set a "hold" rating on the stock in a report on Wednesday, April 15th. Morgan Stanley set a $60.00 target price on Inspire Medical Systems in a research report on Wednesday, February 18th. Finally, Jefferies Financial Group dropped their target price on Inspire Medical Systems from $81.00 to $66.00 and set a "hold" rating on the stock in a research report on Thursday, February 12th.

Institutional Investors Weigh In On Inspire Medical Systems

A number of hedge funds and other institutional investors have recently bought and sold shares of INSP. Manning & Napier Advisors LLC acquired a new stake in Inspire Medical Systems in the 3rd quarter valued at approximately $32,000. CWM LLC raised its position in Inspire Medical Systems by 216.1% in the 4th quarter. CWM LLC now owns 354 shares of the company's stock valued at $33,000 after buying an additional 242 shares during the last quarter. Havemeyer Place LP acquired a new stake in Inspire Medical Systems in the 4th quarter valued at approximately $39,000. V Square Quantitative Management LLC acquired a new stake in Inspire Medical Systems in the 4th quarter valued at approximately $40,000. Finally, Smartleaf Asset Management LLC raised its position in Inspire Medical Systems by 84.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock valued at $42,000 after buying an additional 205 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.

Inspire Medical Systems Price Performance

NYSE:INSP opened at $56.69 on Monday. Inspire Medical Systems has a fifty-two week low of $48.30 and a fifty-two week high of $163.35. The stock has a market capitalization of $1.63 billion, a PE ratio of 11.38, a price-to-earnings-growth ratio of 2.92 and a beta of 0.83. The business's 50-day simple moving average is $56.73 and its 200-day simple moving average is $79.64.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.96. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The business had revenue of $269.08 million for the quarter, compared to analysts' expectations of $264.02 million. During the same quarter in the previous year, the business posted $1.15 EPS. Inspire Medical Systems's revenue for the quarter was up 12.2% on a year-over-year basis. On average, research analysts expect that Inspire Medical Systems will post 1.82 earnings per share for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.